Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

Abstract:

:Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in cancers include the cancer susceptibility genes p53 and BRCA1. Because mutational inactivation of gene function is specific to tumor cells in these settings, cancer gene correction strategies may provide an opportunity for selective targeting without significant toxicity for normal nontumor cells. Both p53 and BRCA1 appear to inhibit cancer cells that lack mutations in these genes, suggesting that the so-called gene correction strategies may have broader potential than initially believed. Increasing knowledge of cancer genetics has identified these and other genes as potential targets for gene replacement therapy. Initial patient trials of p53 and BRCA1 gene therapy have provided some indications of potential efficacy, but have also identified areas of basic and clinical research that are needed before these approaches may be widely used in patient care.

journal_name

Breast Cancer Res

authors

Obermiller PS,Tait DL,Holt JT

doi

10.1186/bcr26

keywords:

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

28-31

issue

1

eissn

1465-5411

issn

1465-542X

journal_volume

2

pub_type

杂志文章,评审
  • The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.

    abstract:BACKGROUND:The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal patients with high-risk breast...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1012-0

    authors: Jensen MB,Lænkholm AV,Nielsen TO,Eriksen JO,Wehn P,Hood T,Ram N,Buckingham W,Ferree S,Ejlertsen B

    更新日期:2018-07-27 00:00:00

  • The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.

    abstract:INTRODUCTION:AIB1, located at 20q12, is a member of the steroid hormone coactivator family. It contains a glutamine repeat (CAG/CAA) polymorphism at its carboxyl-terminal region that may alter the transcriptional activation of the receptor and affect susceptibility to breast cancer through altered sensitivity to hormon...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1009

    authors: Montgomery KG,Chang JH,Gertig DM,Dite GS,McCredie MR,Giles GG,Southey MC,Hopper JL,Campbell IG

    更新日期:2005-01-01 00:00:00

  • Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

    abstract:INTRODUCTION:The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) is a multidisciplinary, collaborative framework for the investigation of familial breast cancer. Based in Australia, the primary aim of kConFab is to facilitate high-quality research by amassing a large and comp...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1377

    authors: Mann GJ,Thorne H,Balleine RL,Butow PN,Clarke CL,Edkins E,Evans GM,Fereday S,Haan E,Gattas M,Giles GG,Goldblatt J,Hopper JL,Kirk J,Leary JA,Lindeman G,Niedermayr E,Phillips KA,Picken S,Pupo GM,Saunders C,Scott CL

    更新日期:2006-01-01 00:00:00

  • Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    abstract:INTRODUCTION:Rapamycin, an inhibitor of the serine/threonine kinase target of rapamycin, induces G1 arrest and/or apoptosis. Although rapamycin and its analogues are attractive candidates for cancer therapy, their sensitivities with respect to growth inhibition differ markedly among various cancer cells. Using human br...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1344

    authors: Kasukabe T,Okabe-Kado J,Kato N,Sassa T,Honma Y

    更新日期:2005-01-01 00:00:00

  • Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort.

    abstract:INTRODUCTION:Vitamin D status measured during adulthood has been inversely associated with breast cancer risk in some, but not all, studies. Vitamin D has been hypothesized to prevent breast cancer through genomic and non-genomic actions in cell-cycle regulation. METHODS:A subset (n = 21,965) of female participants fr...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/bcr2356

    authors: McCullough ML,Stevens VL,Patel R,Jacobs EJ,Bain EB,Horst RL,Gapstur SM,Thun MJ,Calle EE

    更新日期:2009-01-01 00:00:00

  • A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

    abstract:BACKGROUND:Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from local recurrence. Although a mastectomy or adjuvant radiation can reduce recurrence risk, there are sig...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1165-5

    authors: Klimov S,Miligy IM,Gertych A,Jiang Y,Toss MS,Rida P,Ellis IO,Green A,Krishnamurti U,Rakha EA,Aneja R

    更新日期:2019-07-29 00:00:00

  • PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.

    abstract::PIK3CA mutations represent one of the most common genetic aberrations in breast cancer. They have been reported to be present in over one-third of cases, with enrichment in the luminal and in human epidermal growth factor receptor 2-positive subtypes. Substantial preclinical data on the oncogenic properties of these m...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3605

    authors: Zardavas D,Phillips WA,Loi S

    更新日期:2014-01-23 00:00:00

  • Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.

    abstract:INTRODUCTION:The aim of this study was to describe breast tumor subtypes by common breast cancer risk factors and to determine correlates of subtypes using baseline data from two pooled prospective breast cancer studies within a large health maintenance organization. METHODS:Tumor data on 2544 invasive breast cancer c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2261

    authors: Kwan ML,Kushi LH,Weltzien E,Maring B,Kutner SE,Fulton RS,Lee MM,Ambrosone CB,Caan BJ

    更新日期:2009-01-01 00:00:00

  • Genomic signature of parity in the breast of premenopausal women.

    abstract:BACKGROUND:Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal wom...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1128-x

    authors: Santucci-Pereira J,Zeleniuch-Jacquotte A,Afanasyeva Y,Zhong H,Slifker M,Peri S,Ross EA,López de Cicco R,Zhai Y,Nguyen T,Sheriff F,Russo IH,Su Y,Arslan AA,Bordas P,Lenner P,Åhman J,Landström Eriksson AS,Johansson R,H

    更新日期:2019-03-28 00:00:00

  • Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.

    abstract:INTRODUCTION:Activated leukocyte cell adhesion molecule (ALCAM) (CD166) is an immunoglobulin molecule that has been implicated in cell migration. The present study examined the expression of ALCAM in human breast cancer and assessed its prognostic value. METHODS:The immunohistochemical distribution and location of ALC...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr815

    authors: King JA,Ofori-Acquah SF,Stevens T,Al-Mehdi AB,Fodstad O,Jiang WG

    更新日期:2004-01-01 00:00:00

  • Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters?

    abstract::The Developmental Origins of Health and Disease (DOHaD) theory focuses on the consequences of periconceptional and in utero exposures. A wide range of environmental conditions during early development are now being investigated as a driving force for epigenetic disruptions that enhance disease risk in later life, incl...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,社论

    doi:10.1186/s13058-016-0760-y

    authors: Romanus S,Neven P,Soubry A

    更新日期:2016-10-12 00:00:00

  • Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

    abstract::Genome-wide expression microarray studies have revealed that the biological and clinical heterogeneity of breast cancer can be partly explained by information embedded within a complex but ordered transcriptional architecture. Comprising this architecture are gene expression networks, or signatures, reflecting biochem...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1662

    authors: Miller LD,Liu ET

    更新日期:2007-01-01 00:00:00

  • PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.

    abstract:INTRODUCTION:Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase that is highly expressed in Human Epidermal Growth Factor 2(+) (Her2(+)) breast cancers. Overexpression of PTK6 enhances anchorage-independent survival, proliferation, and migration of breast cancer cells. We hypothesized that PTK6 inhibiti...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0594-z

    authors: Park SH,Ito K,Olcott W,Katsyv I,Halstead-Nussloch G,Irie HY

    更新日期:2015-06-19 00:00:00

  • Prognostic stromal gene signatures in breast cancer.

    abstract:INTRODUCTION:Global gene expression analysis of tumor samples has been a valuable tool to subgroup tumors and has the potential to be of prognostic and predictive value. However, tumors are heterogeneous, and homogenates will consist of several different cell types. This study was designed to obtain more refined expres...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0530-2

    authors: Winslow S,Leandersson K,Edsjö A,Larsson C

    更新日期:2015-02-21 00:00:00

  • Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negati

    abstract:INTRODUCTION:Natural herbal compounds with novel actions different from existing breast cancer (BCa) treatment modalities are attractive for improving therapeutic efficacy and safety. We have recently shown that penta-1,2,3,4,6-O-galloyl-β-D-glucose (PGG) induced S-phase arrest in prostate cancer (PCa) cells through in...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2634

    authors: Chai Y,Lee HJ,Shaik AA,Nkhata K,Xing C,Zhang J,Jeong SJ,Kim SH,Lu J

    更新日期:2010-01-01 00:00:00

  • Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.

    abstract:INTRODUCTION:Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer. METHODS:We evaluated the contribution of germline mutations in the DD...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1668

    authors: Broeks A,Braaf LM,Huseinovic A,Nooijen A,Urbanus J,Hogervorst FB,Schmidt MK,Klijn JG,Russell NS,Van Leeuwen FE,Van 't Veer LJ

    更新日期:2007-01-01 00:00:00

  • Breast cancer risk perception: what do we know and understand?

    abstract::Women's perceptions of breast cancer risk are largely inaccurate and are often associated with high levels of anxiety about cancer. There are interesting cultural differences that are not well researched. Genetic risk counselling significantly improves accuracy of women's perceptions of risk, but not necessarily to th...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr83

    authors: Hopwood P

    更新日期:2000-01-01 00:00:00

  • Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

    abstract::Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1149-5

    authors: Rossi L,Biagioni C,McCartney A,Migliaccio I,Curigliano G,Sanna G,Moretti E,Minisini AM,Cinieri S,Tondini C,Arpino G,Bernardo A,Martignetti A,Risi E,Pestrin M,Boni L,Benelli M,Biganzoli L,Di Leo A,Malorni L

    更新日期:2019-05-29 00:00:00

  • A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

    abstract:INTRODUCTION:There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain metastasis. METHODS:We...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3625

    authors: McMullin RP,Wittner BS,Yang C,Denton-Schneider BR,Hicks D,Singavarapu R,Moulis S,Lee J,Akbari MR,Narod SA,Aldape KD,Steeg PS,Ramaswamy S,Sgroi DC

    更新日期:2014-03-14 00:00:00

  • BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.

    abstract:BACKGROUND:The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. METHODS:We have c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr419

    authors: Basham VM,Lipscombe JM,Ward JM,Gayther SA,Ponder BA,Easton DF,Pharoah PD

    更新日期:2002-01-01 00:00:00

  • Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

    abstract:INTRODUCTION:Inhibition of phosphatidylinositol-3-kinase (PI3K) induces apoptosis when combined with estrogen deprivation in estrogen receptor (ER)-positive breast cancer. The aims of the present study were to identify effective PI3K pathway inhibitor and endocrine therapy combinations, to evaluate the effect of PI3K p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2833

    authors: Sanchez CG,Ma CX,Crowder RJ,Guintoli T,Phommaly C,Gao F,Lin L,Ellis MJ

    更新日期:2011-03-01 00:00:00

  • The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.

    abstract:INTRODUCTION:Estrogens play a pivotal role in the initiation and progression of breast cancer. The genes that mediate these processes are not fully defined, but potentially include the known mammary oncogene MYC. Characterization of estrogen-target genes may help to elucidate further the mechanisms of estrogen-induced ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1985

    authors: Butt AJ,Sergio CM,Inman CK,Anderson LR,McNeil CM,Russell AJ,Nousch M,Preiss T,Biankin AV,Sutherland RL,Musgrove EA

    更新日期:2008-01-01 00:00:00

  • Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    abstract:INTRODUCTION:Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable b...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/bcr2363

    authors: Darb-Esfahani S,Loibl S,Müller BM,Roller M,Denkert C,Komor M,Schlüns K,Blohmer JU,Budczies J,Gerber B,Noske A,du Bois A,Weichert W,Jackisch C,Dietel M,Richter K,Kaufmann M,von Minckwitz G

    更新日期:2009-01-01 00:00:00

  • Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.

    abstract:BACKGROUND:Bone is one of the most frequent metastatic sites of advanced breast cancer. Current therapeutic agents aim to inhibit osteoclast-mediated bone resorption but only have palliative effects. During normal bone remodeling, the balance between bone resorption and osteoblast-mediated bone formation is essential f...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1059-y

    authors: Liu X,Cao M,Palomares M,Wu X,Li A,Yan W,Fong MY,Chan WC,Wang SE

    更新日期:2018-10-22 00:00:00

  • Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

    abstract::The key to optimising our approach in early breast cancer is to individualise care. Each patient has a tumour with innate features that dictate their chance of relapse and their responsiveness to treatment. Often patients with similar clinical and pathological tumours will have markedly different outcomes and response...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2238

    authors: Oakman C,Bessi S,Zafarana E,Galardi F,Biganzoli L,Di Leo A

    更新日期:2009-01-01 00:00:00

  • Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

    abstract::Many women newly diagnosed with breast cancer and with a strong family history of breast cancer are referred to a family cancer service for genetic counselling and for consideration of genetic testing for germline mutations in cancer predisposition genes following completion of their cancer treatment. However, there i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2194

    authors: Meiser B,Tucker K,Friedlander M,Barlow-Stewart K,Lobb E,Saunders C,Mitchell G

    更新日期:2008-01-01 00:00:00

  • The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

    abstract:INTRODUCTION:Breast cancers can be classified using whole genome expression into distinct subtypes that show differences in prognosis. One of these groups, the basal-like subtype, is poorly differentiated, highly metastatic, genomically unstable, and contains specific genetic alterations such as the loss of tumour prot...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2142

    authors: Herschkowitz JI,He X,Fan C,Perou CM

    更新日期:2008-01-01 00:00:00

  • Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

    abstract:INTRODUCTION:Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-po...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1363

    authors: Journe F,Chaboteaux C,Magne N,Duvillier H,Laurent G,Body JJ

    更新日期:2006-01-01 00:00:00

  • Relevance of PTEN loss in brain metastasis formation in breast cancer patients.

    abstract:INTRODUCTION:With the improvement of therapeutic options for the treatment of breast cancer, the development of brain metastases has become a major limitation to life expectancy in many patients. Therefore, our aim was to identify molecular markers associated with the development of brain metastases in breast cancer. ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3150

    authors: Wikman H,Lamszus K,Detels N,Uslar L,Wrage M,Benner C,Hohensee I,Ylstra B,Eylmann K,Zapatka M,Sauter G,Kemming D,Glatzel M,Müller V,Westphal M,Pantel K

    更新日期:2012-03-19 00:00:00

  • Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research.

    abstract::The potential for a reduction in dietary fat or for an increase in dietary fiber to reduce breast cancer risk has been debated for some years. It is argued here that available research data, even though extensive, leave open hypotheses ranging from little or no potential to major public health potential for breast can...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr68

    authors: Prentice RL

    更新日期:2000-01-01 00:00:00